Sign In
Buy BYSI
$1.74
+0.0400 (+2.35%)
At Close: Jun 03, 2026
New Stem Cell-Based Application for BeyondSpring’s Plinabulin Presented at ISSCR Annual Meeting
11:00am, Tuesday, 30'th Jun 2020
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that t
BeyondSpring (BYSI) Catches Eye: Stock Jumps 10.9%
04:02am, Wednesday, 24'th Jun 2020
BeyondSpring (BYSI) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSpring’s Plinabulin
12:00pm, Tuesday, 23'rd Jun 2020
BeyondSpring (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology (I/O) therapies, today announced new preclini
BeyondSpring Announces Pricing of Ordinary Shares
09:32am, Friday, 19'th Jun 2020
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the pr
BeyondSpring Announces Proposed Public Offering of Ordinary Shares
08:06pm, Thursday, 18'th Jun 2020
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the la
BeyondSpring (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced positive to
BeyondSpring Reports First-Quarter 2020 Financial Results and Operational Update
12:00pm, Thursday, 11'th Jun 2020
- PROTECTIVE-2 (Study 106) Phase 3 Interim Analysis This Month to Evaluate Superiority in CIN - - PROTECTIVE-2 Phase 2 Shows Positive Results in Chemotherapy Optimization with.
- Plinabulin in Combination with Neulasta Improves Dose and Regimen Compliance of TAC Chemotherapy Compared to Neulasta Alone - - Chemotherapy Dose Reduction and Regimen.
- DSMB Reviewed Over 500 Patients’ Data in Second Interim Analysis to Assess Overall Benefit / Risk with Plinabulin in Second- and Third-Line, EGFR Wild-Type NSCLC - - Data.
BeyondSpring E-Poster Presented at 2020 ASCO Virtual Scientific Program
12:00pm, Tuesday, 02'nd Jun 2020
NEW YORK, June 02, 2020 -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative.
BeyondSpring Granted New U.S. Patent for Plinabulin to Treat Severe Chemotherapy-Induced Neutropenia from Taxane in Cancer Patients
12:00pm, Wednesday, 13'th May 2020
BeyondSpring (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Un
BeyondSpring Inc. (BYSI) CEO Lan Huang on Q4 2019 Results - Earnings Call Transcript
11:31pm, Friday, 01'st May 2020
BeyondSpring Inc. (NASDAQ:BYSI) Q4 2019 Earnings Conference Call April 30, 2020 08:00 AM ET Company Participants Caitlin Kasunich - Senior Vice President, KCSA
BeyondSpring Inc. (BYSI) Q4 2019 Earnings Call Transcript
12:00pm, Friday, 01'st May 2020
Image source: The Motley Fool. BeyondSpring Inc. (NASDAQ: BYSI)Q4 2019 Earnings CallApr 30, 2020, 9:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:
Weekly Research Analysts' Ratings Changes for Beyondspring (BYSI)
08:52am, Friday, 01'st May 2020
Beyondspring (NASDAQ: BYSI) recently received a number of ratings updates from brokerages and research firms: 4/29/2020 – Beyondspring had its “buy” rating reaffirmed by analysts at HC Wainwrigh
BeyondSpring Files 2019 Annual Report on Form 20-F
09:05pm, Thursday, 30'th Apr 2020
NEW YORK, April 30, 2020 -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative.
